Isleworth Healthcare Acquisition Corp. da Cytovia Holdings, Inc. a yau sun ba da sanarwar shiga tabbataccen yarjejeniyar haɗin gwiwar kasuwanci. Bayan kammala wannan haɗin, Isleworth za a sake masa suna Cytovia Therapeutics, Inc. ("kamfanin haɗin gwiwa") kuma ana sa ran samfuran gama-gari da garanti za su kasance a jera su akan NASDAQ a ƙarƙashin alamun tikitin INKC da INKCW, bi da bi.
Haɗin gwiwar kamfanin zai ci gaba da ayyukan Cytovia kuma ya ci gaba da mai da hankali kan haɓakawa da kera kayan aikin NK cell da kuma dandamali na rigakafi na NK.
Kamfanin haɗin gwiwar zai jagoranci Dokta Daniel Teper, Co-Founder, Shugaba, da Babban Jami'in Cytovia.
"Muna godiya da goyon baya mai karfi daga sababbin masu zuba jari da na yanzu da kuma ƙungiyar ƙwararrun ƴan kasuwa a Isleworth. Muna sa ran wannan ciniki zai hanzarta aiwatar da hangen nesa na Cytovia don ciyar da hanyoyin kwantar da hankali na NK zuwa maganin cutar kansa,” in ji Dokta Teper. "An ƙarfafa mu ta hanyar bayanan mu na yau da kullun da aka gabatar a AACR, wanda ke tallafawa haɓaka ci gaban sel NK da aka samu na iPSC (iNK) da Flex-NK ™ cell masu shiga don maganin cutar sankara na Hepatocellular."
Bob Whitehead, Shugaba na Isleworth, ya ce: “Isleworth ta kimanta kamfanonin kimiyyar rayuwa da yawa kuma ta fi burge da hazaka da fasahar da Cytovia ta tattara. Mun yi imanin Cytovia ɗaya ce daga cikin ci-gaba, sabbin kamfanoni masu warkar da ƙwayoyin cuta waɗanda ke da hannu tare da haɓaka sabbin hanyoyin magance cutar kansa. Magungunan ƙwayoyin cuta a cikin ƙwayoyin cuta sun riga sun kawo bege ga miliyoyin. Hanyoyi na Cytovia na iya yin la'akari da yin irin wannan hanyoyin mafi dacewa da 'off-self' kuma mai araha. "
Hanyar warkewa ta Cytovia
Cytovia na da nufin haɓaka damar samun majiyyaci zuwa hanyoyin gyaran ƙwayoyin sel da na rigakafi, da magance da yawa daga cikin mafi ƙalubale na buƙatun likita waɗanda ba a cika su ba a cikin ilimin oncology.
Kamfanin yana mai da hankali kan yin amfani da tsarin rigakafi na asali ta hanyar haɓaka hanyoyin haɗin gwiwa da ɓarnawar NK-cell da dandamalin rigakafin jiki na NK. Musamman, Cytovia yana haɓaka nau'ikan ƙwayoyin iNK guda uku: sel iNK da ba a gyara su ba, TALEN® gene-edited iNK cells tare da ingantaccen aiki da tsayin daka, da TALEN® da aka gyara ta ƙwayoyin iNK tare da masu karɓar antigen na chimeric (CAR-iNKs) don haɓaka takamaiman ƙari. niyya. Fasaha na gaba ta biyu ta ginshiƙi dandamali ce ta musamman ta musamman wacce aka ƙera don haɗa ƙwayoyin NK ta hanyar niyya mai karɓar mai kunnawa NKp46 ta amfani da fasahar Flex-NK™ ta mallaka.
Ana amfani da waɗannan dandamali na fasaha guda biyu don haɓaka jiyya ga marasa lafiya da ke fama da ciwon Hanta (HCC) da kuma ciwace-ciwace. Ana sa ran fara karatun asibiti a ƙarshen 2022.
Wanda yake da hedikwata a Aventura, FL, Cytovia yana aiki da dakunan gwaje-gwaje na R&D a Natick, MA da kuma masana'antar masana'anta ta cGMP a Puerto Rico kuma yana da haɗin gwiwar kimiyya tare da Cellectis, CytoImmune Therapeutics, Jami'ar Ibrananci ta Urushalima, INSERM, Gidauniyar Stem Cell ta New York, Nationalasa. Cibiyar Cancer, da Jami'ar California San Francisco (UCSF). Cytovia Therapeutics kwanan nan ya kafa CytoLynx Therapeutics, haɗin gwiwar dabarun da aka mayar da hankali kan bincike da haɓakawa, masana'antu, da ayyukan tallace-tallace a cikin Babban Sin da sauran su.
Cytovia Pipeline
Cytovia ita ce kamfani na farko na rigakafi-oncology tare da damar haɗa kwayar halittar iPSC-wanda aka samu NK Cell da Flex-NK™ cell mai shigar da ƙwayoyin rigakafin ƙwayoyin cuta don haɓaka ƙarni na gaba na rigakafi na rigakafi don duka ciwon jini da ƙwararrun ciwace-ciwace.
Fayil ɗin Cytovia ya haɗa da hari da alamu tare da daidaitaccen bayanin haɗarin haɗari.
GPC3 sabon labari ne mai ban sha'awa ga ciwace-ciwacen ciwace-ciwacen daji, musamman ciwon hanta, inda buƙatun likita da ba a biya su ba ya fi mahimmanci. Shirin jagorar Cytovia yana nufin haɓaka hanyoyin kwantar da hankali na HCC na farko da ke nufin GPC3. Za a ƙididdige ƴan takarar samfurin farko guda huɗu azaman maganin warkewa guda ɗaya kuma azaman hanyoyin haɗin gwiwa. CYT-303, Cytovia's GPC3 Flex-NK™ mai shiga tsakani, wani takamaiman antibody ne wanda ke ɗaure ga ƙwayoyin tumor HCC ta hanyar GPC3 da kuma ƙwayoyin NK ta hanyar NKp46 da CD16a. Ga marasa lafiya tare da ko dai lambar da ba ta da kyau ko aiki na ƙwayoyin NK, Cytovia za ta kimanta ƙarin ƙwayoyin iNK, CYT-100, don yiwuwar buɗe cikakkiyar damar wannan dabarun magani. Cytovia kuma tana haɓaka CYT-150, ƙwayoyin iNK da aka gyara ta gene, don haɓaka ƙwayar ƙwayar cuta da dagewar tantanin halitta, wanda kuma ana iya haɗa shi da CYT-303. Bugu da ƙari, CYT-503, GPC3-targeting CAR-iNK cell therapeutic, an ƙera shi don inganta ƙayyadaddun ƙayyadaddun ƙwayar ƙwayar cuta. Cytovia tana tsammanin shigar da IND don CYT-303 da CYT-100, sannan IND don CYT-150 da CYT-503.
CD38 shine ingantacciyar manufa ta asibiti da kasuwanci don Multiple Myeloma. Cytovia tana haɓaka CYT-338 da CYT-538 waɗanda, bi da bi, CD38-targeting Flex-NK™ cell engagers da CAR-iNK Kwayoyin don kula da Multiple Myeloma a cikin marasa lafiya da suka kasa CD38 antibody hanyoyin kwantar da hankali da kuma jamiái da ke niyya B-cell maturation. antigen (BCMA).
Cytovia kuma tana haɓaka ɗan takarar EGFR CAR iNK na ciki don yin niyya ga wtEGFR da EGFR vIII don magance babban buƙatun likita a cikin sarrafa Glioblastoma multiforme a halin yanzu ba za a iya magance shi ba.
Cytovia ta kafa haɗin gwiwa tare da cibiyoyin ilimi da abokan hulɗar masana'antu ciki har da Cellectis don TALEN® editan kwayoyin halitta. TALEN® editan kwayoyin halitta fasaha ce ta farko da Cellectis ke sarrafa shi, wani kamfani na kimiyyar halittu na matakin asibiti wanda ke amfani da dandamalin gyaran kwayoyin halittarsa don haɓaka ƙwayoyin ceton rai da hanyoyin warkewar kwayoyin halitta. Abubuwan haƙƙin mallaka na TALEN® da aka daidaita ta hanyar Cellectis a fagen iNK da CAR-iNK suna da lasisi daga Cellectis ta Cytovia kuma Cytovia tana riƙe da ci gaban duniya da haƙƙin kasuwanci ga waɗannan haƙƙin mallaka.
Shirye-shiryen Milestones da Amfani da Ci gaba
Abubuwan da aka samu daga wuraren zama masu zaman kansu ("PIPE"), kuɗi a cikin asusun amintaccen Isleworth (net of fansa), da kuma kuɗin da aka samu daga sauran kuɗaɗen da ake son samu, a cikin jimillar adadin da ya kai dala miliyan ɗari, zai ba wa Cytovia babban jari har zuwa 2. shekaru don ci gaba da haɓaka fasahar sa ta iNK da Flex-NK™ da aka gyara ta. Cytovia na shirin mayar da hankali kan matakai masu yawa, gami da:
• Aiwatar da IND guda biyu na farko don Flex-NK™ CYT-303 da iNK CYT-100
• Ƙaddamar da gwaji na asibiti na Phase I / II don kimanta CYT-303 da CYT-100, kadai kuma a hade, don maganin HCC.
• Samun da gabatar da bayanan asibiti na farko don CYT-303 da CYT-100 a cikin HCC
• Aiwatar da INDs don CYT-150 da CYT-503 da fara gwajin gwajin asibiti na Phase I/II
• Ci gaba da haɓaka fasahar iNK & Flex-NK™ da haɓaka bututun tare da ƴan takarar warkewa da yawa.
